Blockade of nitric oxide formation impairs adrenergic-induced ACTH and corticosterone secretion.
It has been suggested that adrenergic agents might modulate the L-arginine-NO pathway. Sympathomimetic agonists enhance the basal release of NO, and noradrenaline increases the synthesis of nitric oxide synthase (NOS) in the medial basal hypothalamus in vitro. In the present study possible involvement of NO in central stimulation of the hypothalamic-pituitary-adrenal (HPA) axis by adrenergic agents was investigated in conscious rats. The nitric oxide synthase blocker N(omega)-nitro-L-arginine methyl ester (L-NAME 2 and 10 microg) was administered intracerebroventricularly (i.c.v.) 15 min before the adrenergic agonist given by the same route; 1 h later the rats were decapitated. Plasma levels of ACTH and corticosterone were measured. L-NAME significantly diminished the ACTH and corticosterone response to phenylephrine (30 microg), an alpha1-adrenergic receptor agonist. These hormone responses to clonidine (10 microg), an alpha2-receptor agonist, were dose-dependently suppressed or totally abolished by L-NAME. A significant rise in the ACTH and corticosterone secretion induced by isoprenaline (10 microg), a beta-adrenergic receptor agonist, was only moderately diminished by pretreatment with L-NAME. These results indicate that NOS is considerably involved in central stimulation of the HPA axis by alpha1- and alpha2-adrenergic receptor agonists, and that NO mediates the stimulatory action of these agonists on ACTH and corticosterone secretion. The stimulation induced by beta-adrenergic receptors is only moderately affected by endogenous NO.
Bugajski
J
J
Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Cracow. bugajski@if-pan.krakow.pl
Gadek-Michalska
A
A
Głód
R
R
Borycz
J
J
Bugajski
A J
AJ
D000322:Adrenergic Agonists / Q000008:administration & dosage*; D000324:Adrenocorticotropic Hormone / Q000097:blood* / Q000187:drug effects; D000818:Animals; D003000:Clonidine / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000502:physiology; D052248:Nitric Oxide Synthase Type I; D010656:Phenylephrine / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D011941:Receptors, Adrenergic / Q000187:drug effects
D000322:Adrenergic Agonists; D004791:Enzyme Inhibitors; D011941:Receptors, Adrenergic; D010656:Phenylephrine; D009569:Nitric Oxide; D000324:Adrenocorticotropic Hormone; D019001:Nitric Oxide Synthase; D052248:Nitric Oxide Synthase Type I; C496322:Nos1 protein, rat; D007545:Isoproterenol; D003000:Clonidine; D019331:NG-Nitroarginine Methyl Ester; D003345:Corticosterone